Mentus

Mendus is a clinical-stage biopharmaceutical company headquartered in Sweden, dedicated to developing novel immunotherapies for cancer maintenance and the prevention of tumor recurrence. The company's core technology is the DCOne platform, which utilizes an allogeneic dendritic cell line to stimulate a robust and durable immune response against a broad range of tumor-associated antigens. Its lead program, vididencel, is currently being evaluated in Phase 2 clinical trials for the treatment of acute myeloid leukemia (AML) and ovarian cancer. By focusing on the maintenance phase of cancer treatment, Mendus aims to extend survival and improve the quality of life for patients who have achieved initial remission but remain at high risk of relapse.